ipilimumablifileucelnivolumabLifileucel-induced
…en of nausea and vomiting was reported in patients treated with ipilimumab. 55From patient selection to TIL expansion: a comprehensive ove…
17articles mentioning drugs
22drug mentions
1distinct drugs extracted
0%of mentions human-reviewed
Active filtersEntity: fludarabine ×
fludarabine
This drug is selected. Its supporting articles are shown below.
Articles mentioning fludarabine
17 articles · page 1 of 2rapcabtagene autoleucelcyclophosphamidefludarabineDiffuse cutaneous systemic sclerosis (dcSSc)Novartis Pharma AGdcSScCD19-targeted chimeric antigen receptor (CAR)-T cell therapy
…e and fludarabine, followed by a single intravenous infusion of rapcabtagene autoleucel, with the initial three dosed sequentially with a 28-day observ…
mycophenolate mofetilmethotrexatecyclophosphamiderituximabfludarabineanti-thymocyte globulinDiffuse cutaneous systemic sclerosis (dcSSc)dcSSc
… AHSCT after failing standard therapies including methotrexate, mycophenolate mofetil, cyclophosphamide, and rituximab. The conditioning regimen cons…
cyclophosphamidefludarabineSheba Medical Centrediffuse progressive systemic sclerosis (SSc)Chimeric Antigen Receptor T-cell (CAR-T) therapy
…temic sclerosis (SSc), improving overall survival compared with cyclophosphamide. However, 10–20% of patients relapse after AHSCT. Chimeric Anti…
cyclophosphamidefludarabinerese-celsystemic sclerosis (SSc)SSc-Skin-1SSc-Skin-2SSc-Skin-1Abstract
…was administered following preconditioning with fludarabine and cyclophosphamide. All non-glucocorticoid (GC) IM agents were stopped by Day -5. …
fludarabinecyclophosphamideCD19-targeting CAR T cellsUniversity hospital ErlangenCD19-targeting CAR T cell therapyautoimmune diseases
…nfusion and the therapy was performed upon lymphodepletion with fludarabine (25 mg/m2 on days -5, -4, -3) and cyclophosphamide (1g/m2 on da…
polatuzumabrituximabAxi-celdarunaviraxicabtagene ciloleucelemtricitabinefludarabinetenofovirnon-Hodgkin lymphomaonco-hematological malignancies+1 more
…y with axicabtagene ciloleucel (axi-cel). Bridging therapy with polatuzumab plus rituximab, followed by Axi-cel infusion after a standard l…
1338 Multi-cohort phase II study of autologous centrally manufactured tumor infiltrating lymphocytes
cyclophosphamidefludarabineIL-2melanomaovarian canceranaplastic thyroid cancerMD Anderson IRB
…neration. After successful TIL production, lymphodepletion with cyclophosphamide (60mg/kg/day IV on days -7 and -6) and fludarabine (25mg/m2 IV …
Cy/FlucyclophosphamidefludarabineIL-12 GEMysOsteosarcomarhabdomyosarcomaNational Institutes of HealthIL-12 GEMy therapy
…ated by an immunosuppressive myeloid infiltrate. Treatment with Cy/Flu depleted most circulating immune cells and TAMs. Cy/Flu plus IL…
fludarabinecyclophosphamiderecombinant human IL-2cancerosteosarcomaUniversity of Wisconsin Institutional Animal Care and Use Committeehuman malignancies
…ex vivo expanded allogeneic NK cells after lymphodepletion with fludarabine and cyclophosphamide. Canines were given subcutaneous recombina…
nivolumabcyclophosphamidepembrolizumabfludarabinealdesleukinhematologic cancersWCG IRBmetastatic HPV-associated cancersmetastatic HPV-associated epithelial cancersepithelial cancers
…nt with anal cancer previously treated with 5 agents, including nivolumab. The duration of the complete responses is 8 months and 9 month…
ANV419fludarabinecyclophosphamidemelanomaPragmaTIL network
… The BaseTIL-03M trial demonstrates that combining TIL-ACT with ANV419 is feasible and well tolerated, with no dose-limiting toxicitie…